204 related articles for article (PubMed ID: 20943616)
1. Proteomics as a guiding tool for more effective personalized therapy.
Lee JM; Kohn EC
Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling in ovarian cancer.
Kim G; Minig L; Kohn EC
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
[TBL] [Abstract][Full Text] [Related]
3. Prognostic biomarkers in ovarian cancer.
Huang J; Hu W; Sood AK
Cancer Biomark; 2010-2011; 8(4-5):231-51. PubMed ID: 22045356
[TBL] [Abstract][Full Text] [Related]
4. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
Posadas EM; Davidson B; Kohn EC
Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
[TBL] [Abstract][Full Text] [Related]
5. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry based proteomics and metabolomics in personalized oncology.
Kowalczyk T; Ciborowski M; Kisluk J; Kretowski A; Barbas C
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165690. PubMed ID: 31962175
[TBL] [Abstract][Full Text] [Related]
7. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
Kelleher MT; Fruhwirth G; Patel G; Ofo E; Festy F; Barber PR; Ameer-Beg SM; Vojnovic B; Gillett C; Coolen A; Kéri G; Ellis PA; Ng T
Target Oncol; 2009 Sep; 4(3):235-52. PubMed ID: 19756916
[TBL] [Abstract][Full Text] [Related]
8. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
11. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
13. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
14. Proteomics and ovarian cancer: integrating proteomics information into clinical care.
Hays JL; Kim G; Giuroiu I; Kohn EC
J Proteomics; 2010 Sep; 73(10):1864-72. PubMed ID: 20561909
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer.
Zhao M; Shen F; Yin YX; Yang YY; Xiang DJ; Chen Q
Reprod Sci; 2012 Jul; 19(7):748-53. PubMed ID: 22534325
[TBL] [Abstract][Full Text] [Related]
16. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
17. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Zhu J; Wang H; Liu CC; Lu Y; Tang H
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
[TBL] [Abstract][Full Text] [Related]
18. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
19. [Epithelial ovarian cancer - a change of paradigm].
Heinzelmann-Schwarz V
Ther Umsch; 2011 Oct; 68(10):565-72. PubMed ID: 21968896
[TBL] [Abstract][Full Text] [Related]
20. Proteomics and biomarkers in clinical trials for drug development.
Lee JM; Han JJ; Altwerger G; Kohn EC
J Proteomics; 2011 Nov; 74(12):2632-41. PubMed ID: 21570499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
